|These human Thy-1-COX-2 transgenic mice have expression of human COX-2 (PTGS2 or PGE2) directed primarily to neurons of the amygdala, striatum, cerebral cortex, and hippocampus by the murine Thy1.2 expression cassette. These mice may be useful to model chronic elevations in COX-2 enzymatic activity associated with neurodegenerative diseases and aging, oxidative metabolism of endocannabinoids in modulation of synaptic transmission and plasticity, and ischemia and postischemic inflammatory reaction.|
Former Names C57BL/6J-Tg(Thy1-PTGS2)300Kand/J (Changed: 22-SEP-11 ) Type Coisogenic; Mutant Strain; Transgenic; Additional information on Genetically Engineered and Mutant Mice. Visit our online Nomenclature tutorial. Species laboratory mouse Donating Investigator Katrin I Andreasson, Stanford University
Mice hemizygous for the human Thy-1-COX-2 transgene (hCOX-2 transgene) are viable and fertile, with expression of human COX-2 (PTGS2 or PGE2) directed primarily to neurons of the amygdala, striatum, cerebral cortex, and hippocampus by the murine Thy1.2 expression cassette. These moderate overexpressing C57BL/6J COX-2 transgenic line 300 mice have PGE2 levels that are ~10-12-fold greater than non-transgenic controls (compared to ~25-40-fold overexpression in line 303; see Stock No. 010703). At approximately 12 months of age, COX-2 transgenic mice develop an age-dependent deficit in spatial memory. Around 20 months of age, a less pronounced, but significant deterioration in performance of non-spatial memory tasks develops. Further progressive memory impairments are observed over time. These cognitive deficits are associated with parallel age-dependent increases in cortical neuronal apoptosis and glial activation. Transgenic mice exhibit enhanced hippocampal longterm synaptic plasticity. Chronic overexpression of neuronal COX-2 enzymatic activity leads to long-term cellular changes that result in diminished neuron viability in transient focal ischemia/ischemic injury challenge. Elevated expression of COX-2 leads to increased oxidative degradation of endocannabinoids (eCBs); resulting in abolished depolarization-induced suppression of inhibition (DSI; or eCB-induced suppression of GABAergic synaptic transmission). These human Thy-1-COX-2 transgenic mice may be useful to model chronic elevations in COX-2 enzymatic activity associated with neurodegenerative diseases and aging, oxidative metabolism of endocannabinoids in modulation of synaptic transmission and plasticity, and ischemia and postischemic inflammatory reaction.
The human Thy-1-COX-2 transgene (hCOX-2 transgene) was designed with the entire 1.8 kb human COX-2 (PTGS2; prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) or PGE2) open reading frame sequence inserted into the 8.2 kb Thy-1 expression cassette (in the second exon of the "murine Thy-1.2 gene"). This transgene was injected into the male pronucleus of C57BL/6J cells. Transgenic founders were bred with C57BL/6J and mice from founder line 300 were found to have an approximately 10-12-fold increase in PGE2 expression. Transgenic mice were bred with C57BL/6NCrl mice for approximately five years prior to sending to The Jackson Laboratory Repository. Upon arrival, sperm from transgenic mice was cryopreserved. When rederiving the live colony, transgenic sperm will be used to fertilize oocytes from C57BL/6NJ females (Stock No. 005304).
|Considerations for Choosing Controls|
Alzheimer's Disease Models
005987 129-Achetm1Loc/J 006409 129S1.129(Cg)-Tg(APPSw)40Btla/Mmjax 008077 129S1/Sv-Bchetm1Loc/J 016198 129S6.Cg-Tg(Camk2a-tTA)1Mmay/JlwsJ 014556 129S6/SvEv-Apoetm4Mae/J 006555 A.129(B6)-Tg(APPSw)40Btla/Mmjax 005708 B6.129-Apbb1tm1Quhu/J 004714 B6.129-Bace1tm1Pcw/J 004098 B6.129-Klc1tm1Gsn/J 004193 B6.129-Psen1tm1Mpm/J 003615 B6.129-Psen1tm1Shn/J 005300 B6.129-Tg(APPSw)40Btla/Mmjax 005617 B6.129P-Psen2tm1Bdes/J 002609 B6.129P2-Nos2tm1Lau/J 007685 B6.129P2-Psen1tm1Vln/J 007999 B6.129P2-Sorl1Gt(Ex255)Byg/J 008087 B6.129S1-Bchetm1Loc/J 002509 B6.129S2-Plautm1Mlg/J 005301 B6.129S2-Tg(APP)8.9Btla/J 004163 B6.129S4-Cdk5r1tm1Lht/J 010959 B6.129S4-Grk5tm1Rjl/J 010960 B6.129S4-Grk5tm2Rjl/J 002213 B6.129S4-Ngfrtm1Jae/J 006406 B6.129S4-Tg(APPSwLon)96Btla/Mmjax 006469 B6.129S4-Tg(PSEN1H163R)G9Btla/J 012564 B6.129S5-Dhcr24tm1Lex/SbpaJ 004142 B6.129S7-Aplp2tm1Dbo/J 004133 B6.129S7-Apptm1Dbo/J 007251 B6.129X1-Mapttm1Hnd/J 013040 B6.Cg-Apoetm1Unc Ins2Akita/J 005642 B6.Cg-Clutm1Jakh/J 005491 B6.Cg-Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J 009126 B6.Cg-Nos2tm1Lau Tg(Thy1-APPSwDutIowa)BWevn/Mmjax 005866 B6.Cg-Tg(APP695)3Dbo Tg(PSEN1dE9)S9Dbo/Mmjax 008730 B6.Cg-Tg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas/Mmjax 005864 B6.Cg-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax 007575 B6.Cg-Tg(CAG-Ngb,-EGFP)1Dgrn/J 016197 B6.Cg-Tg(CAG-OTC/CAT)4033Prab/J 005855 B6.Cg-Tg(Camk2a-Prkaca)426Tabe/J 007004 B6.Cg-Tg(Camk2a-tTA)1Mmay/DboJ 004996 B6.Cg-Tg(DBH-Gal)1923Stei/J 007673 B6.Cg-Tg(Gad1-EGFP)3Gfng/J 004662 B6.Cg-Tg(PDGFB-APP)5Lms/J 006293 B6.Cg-Tg(PDGFB-APPSwInd)20Lms/2Mmjax 006006 B6.Cg-Tg(Prnp-APP)A-2Dbo/J 008596 B6.Cg-Tg(Prnp-Abca1)EHol/J 006005 B6.Cg-Tg(Prnp-App/APPswe)E1-2Dbo/Mmjax 007180 B6.Cg-Tg(Prnp-ITM2B/APP695*40)1Emcg/J 007182 B6.Cg-Tg(Prnp-ITM2B/APP695*42)A12Emcg/J 005999 B6.Cg-Tg(SBE/TK-luc)7Twc/J 012597 B6.Cg-Tg(Thy1-COL25A1)861Yfu/J 007051 B6.Cg-Tg(tetO-APPSwInd)102Dbo/Mmjax 007052 B6.Cg-Tg(tetO-APPSwInd)107Dbo/Mmjax 007049 B6.Cg-Tg(tetO-APPSwInd)885Dbo/Mmjax 009337 B6.FVB-Tg(Prnp-RTN3)2Yanr/J 006394 B6;129-Apba2tm1Sud Apba3tm1Sud Apba1tm1Sud/J 008364 B6;129-Chattm1(cre/ERT)Nat/J 008476 B6;129-Ncstntm1Sud/J 004807 B6;129-Psen1tm1Mpm Tg(APPSwe,tauP301L)1Lfa/Mmjax 007605 B6;129P-Psen1tm1Vln/J 005618 B6;129P2-Bace2tm1Bdes/J 008333 B6;129P2-Dldtm1Ptl/J 002596 B6;129P2-Nos2tm1Lau/J 003822 B6;129S-Psen1tm1Shn/J 012639 B6;129S4-Mapttm3(HDAC2)Jae/J 012869 B6;129S6-Apbb2tm1Her/J 006410 B6;129S6-Chattm2(cre)Lowl/J 005993 B6;129S6-Pcsk9tm1Jdh/J 008636 B6;C-Tg(Prnp-APP695*/EYFP)49Gsn/J 007002 B6;C3-Tg(Prnp-ITM2B/APP695*42)A12Emcg/Mmjax 008169 B6;C3-Tg(Prnp-MAPT*P301S)PS19Vle/J 000231 B6;C3Fe a/a-Csf1op/J 008850 B6;SJL-Tg(Mt1-LDLR)93-4Reh/AgnJ 003378 B6C3-Tg(APP695)3Dbo Tg(PSEN1)5Dbo/J 004462 B6C3-Tg(APPswe,PSEN1dE9)85Dbo/Mmjax 003741 B6D2-Tg(Prnp-MAPT)43Vle/J 016556 B6N.129-Ptpn5tm1Pjlo/J 018957 B6N.129S6(B6)-Chattm2(cre)Lowl/J 024841 B6N.Cg-Tg(Prnp-MAPT*P301S)PS19Vle/J 006554 B6SJL-Tg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas/Mmjax 012621 C.129S(B6)-Chrna3tm1.1Hwrt/J 002328 C.129S2-Plautm1Mlg/J 003375 C3B6-Tg(APP695)3Dbo/Mmjax 005087 C57BL/6-Tg(Camk2a-IDE)1Selk/J 005086 C57BL/6-Tg(Camk2a-MME)3Selk/J 008833 C57BL/6-Tg(Camk2a-UBB)3413-1Fwvl/J 007027 C57BL/6-Tg(Thy1-APPSwDutIowa)BWevn/Mmjax 010703 C57BL/6-Tg(Thy1-PTGS2)303Kand/J 005706 C57BL/6-Tg(tetO-CDK5R1/GFP)337Lht/J 006618 C57BL/6-Tg(tetO-COX8A/EYFP)1Ksn/J 007677 CB6-Tg(Gad1-EGFP)G42Zjh/J 007072 CByJ.129P2(B6)-Nos2tm1Lau/J 006472 D2.129(B6)-Tg(APPSw)40Btla/Mmjax 007067 D2.129P2(B6)-Apoetm1Unc/J 013719 D2.Cg-Apoetm1Unc Ins2Akita/J 003718 FVB-Tg(GadGFP)45704Swn/J 013732 FVB-Tg(NPEPPS)1Skar/J 013156 FVB-Tg(tetO-CDK5R1*)1Vln/J 015815 FVB-Tg(tetO-MAPT*P301L)#Kha/JlwsJ 002329 FVB.129S2-Plautm1Mlg/J 003753 FVB/N-Tg(Eno2CDK5R1)1Jdm/J 006143 FVB/N-Tg(Thy1-cre)1Vln/J 008051 NOD.129P2(B6)-Ctsbtm1Jde/RclJ 008390 STOCK Apptm1Sud/J 012640 STOCK Hdac2tm1.2Rdp/J 004808 STOCK Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J 004779 STOCK Mapttm1(EGFP)Klt/J 014092 STOCK Tg(ACTB-tTA2,-MAPT/lacZ)1Luo/J 014544 STOCK Tg(tetO-ABL1*P242E*P249E)CPdav/JView Alzheimer's Disease Models (109 strains)Strains carrying other alleles of PTGS2View Strains carrying other alleles of PTGS2 (1 strain)Strains carrying other alleles of Thy1
005895 B10.Cg-Thy1a H2d Tg(TcraCl1,TcrbCl1)1Shrm/J 001317 B6.Cg-Gpi1a Thy1a Igha/J 017798 B6.Cg-Mapttm1Hnd Tg(Thy1-MAPT*)3610Gds/Mmjax 009126 B6.Cg-Nos2tm1Lau Tg(Thy1-APPSwDutIowa)BWevn/Mmjax 022073 B6.Cg-Rag1tm1Mom Thy1a Tg(Tcra2C,Tcrb2C)1Dlo/J 014550 B6.Cg-Thy1a Tg(TcraCWM5,TcrbCWM5)1807Wuth/J 005023 B6.Cg-Thy1a/Cy Tg(TcraTcrb)8Rest/J 008730 B6.Cg-Tg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas/Mmjax 007901 B6.Cg-Tg(Thy1-Brainbow1.0)HLich/J 007911 B6.Cg-Tg(Thy1-Brainbow1.1)MLich/J 007921 B6.Cg-Tg(Thy1-Brainbow2.1)RLich/J 003710 B6.Cg-Tg(Thy1-CFP)23Jrs/J 014131 B6.Cg-Tg(Thy1-CFP)IJrs/GfngJ 007940 B6.Cg-Tg(Thy1-CFP/COX8A)C1Lich/J 007967 B6.Cg-Tg(Thy1-CFP/COX8A)S2Lich/J 012597 B6.Cg-Tg(Thy1-COL25A1)861Yfu/J 007612 B6.Cg-Tg(Thy1-COP4/EYFP)18Gfng/J 007615 B6.Cg-Tg(Thy1-COP4/EYFP)9Gfng/J 013161 B6.Cg-Tg(Thy1-Clomeleon)1Gjau/J 007919 B6.Cg-Tg(Thy1-EGFP)OJrs/GfngJ 005630 B6.Cg-Tg(Thy1-EYFP)15Jrs/J 009611 B6.Cg-Tg(Thy1-Nlgn1)6Hnes/J 009612 B6.Cg-Tg(Thy1-Nlgn2)6Hnes/J 021069 B6.Cg-Tg(Thy1-PA-GFP)5Rmpl/J 021070 B6.Cg-Tg(Thy1-PA-GFP)6Rmpl/J 003709 B6.Cg-Tg(Thy1-YFP)16Jrs/J 003782 B6.Cg-Tg(Thy1-YFP)HJrs/J 005627 B6.Cg-Tg(Thy1-YFP/Syp)10Jrs/J 007606 B6.Cg-Tg(Thy1-cre/ERT2,-EYFP)AGfng/J 025854 B6.FVB-Ptprca Tg(CAG-luc,-GFP)L2G85Chco Thy1a/J 000406 B6.PL-Thy1a/CyJ 000983 B6.PL/(84NS)CyJ 004807 B6;129-Psen1tm1Mpm Tg(APPSwe,tauP301L)1Lfa/Mmjax 007910 B6;CBA-Tg(Thy1-Brainbow1.0)LLich/J 011070 B6;CBA-Tg(Thy1-EGFP)SJrs/NdivJ 017892 B6;CBA-Tg(Thy1-GCaMP2.2c)8Gfng/J 017893 B6;CBA-Tg(Thy1-GCaMP3)6Gfng/J 014130 B6;CBA-Tg(Thy1-YFP)GJrs/GfngJ 014651 B6;CBA-Tg(Thy1-spH)21Vnmu/J 015814 B6;CBA-Tg(Thy1-spH)64Vnmu/FrkJ 012341 B6;SJL-Tg(Thy1-COP3/EYFP)1Gfng/J 012344 B6;SJL-Tg(Thy1-COP3/EYFP)4Gfng/J 012348 B6;SJL-Tg(Thy1-COP3/EYFP)8Gfng/J 012350 B6;SJL-Tg(Thy1-COP4*H134R/EYFP)20Gfng/J 008004 B6;SJL-Tg(Thy1-ECFP/VAMP2)1Sud/J 012836 B6;SJL-Tg(Thy1-TARDBP)4Singh/J 007610 B6;SJL-Tg(Thy1-cre/ERT2,-EYFP)VGfng/J 012332 B6;SJL-Tg(Thy1-hop/EYFP)2Gfng/J 012334 B6;SJL-Tg(Thy1-hop/EYFP)4Gfng/J 006554 B6SJL-Tg(APPSwFlLon,PSEN1*M146L*L286V)6799Vas/Mmjax 025401 B6SJL-Tg(Thy1-COX8A/Dendra)57Gmnf/J 017590 B6SJL-Tg(Thy1-DCTN1*G59S)M2Pcw/J 007880 B6SJL-Tg(Thy1-Stx1a/EYFP)1Sud/J 007856 B6SJL-Tg(Thy1-Syt1/ECFP)1Sud/J 017589 B6SJL-Tg(Thy1-TARDBP*G298S)S97Pcw/J 017351 BKa.Cg-Ptprcb Bmi1tm1Ilw Thy1a/J 007687 BKa.Cg-Sox17tm1Sjm Ptprcb Thy1a/J 007686 BKa.Cg-Sox17tm2Sjm Ptprcb Thy1a/J 024703 C3A.Cg-Pde6b+Tg(Thy1-CFP)23Jrs/SjJ 007027 C57BL/6-Tg(Thy1-APPSwDutIowa)BWevn/Mmjax 010703 C57BL/6-Tg(Thy1-PTGS2)303Kand/J 012769 C57BL/6-Tg(Thy1-Sncg)HvP36Putt/J 024339 C57BL/6J-Tg(Thy1-GCaMP6f)GP5.11Dkim/J 025393 C57BL/6J-Tg(Thy1-GCaMP6f)GP5.17Dkim/J 024276 C57BL/6J-Tg(Thy1-GCaMP6f)GP5.5Dkim/J 025776 C57BL/6J-Tg(Thy1-GCaMP6s)GP4.12Dkim/J 024275 C57BL/6J-Tg(Thy1-GCaMP6s)GP4.3Dkim/J 025533 C57BL/6N-Sncatm1Mjff Tg(Thy1-SNCA)15Mjff/J 016936 C57BL/6N-Tg(Thy1-SNCA)12Mjff/J 017682 C57BL/6N-Tg(Thy1-SNCA)15Mjff/J 005307 CBy.Cg-Thy1a Tg(TcraCl4,TcrbCl4)1Shrm/ShrmJ 005922 CBy.Cg-Thy1a Tg(TcraCl1,TcrbCl1)1Shrm/J 005443 CBy.PL(B6)-Thy1a/ScrJ 024704 D2.Cg-Gpnmb+Tg(Thy1-CFP)23Jrs/SjJ 025018 D2.Cg-Gpnmb+Tg(Thy1-YFP)HJrs/SjJ 018671 D2.Cg-Tg(Thy1-CFP)23Jrs/SjJ 024705 D2.Cg-Tg(Thy1-YFP)HJrs/SjJ 025019 D2.Cg-Tg(Thy1-YFP/Syp)10Jrs/SjJ 008230 FVB(Cg)-Tg(Thy1-SOD1*G93A)T3Hgrd/J 006143 FVB/N-Tg(Thy1-cre)1Vln/J 024476 NOD.Cg-Stat4tm1Gru Thy1a Ifngr1tm1Agt Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/LmbrJ 005686 NOD.Cg-Thy1a Tg(TcraCl4,TcrbCl4)1Shrm/ShrmJ 004483 NOD.NON-Thy1a/1LtJ 002721 NOD.NON-Thy1a/J 005651 SJL.AK-Thy1a/TseJ 003961 SJL.Cg Thy1a-Noxo1hslt/J 021226 STOCK Tg(Thy1-Brainbow3.1)18Jrs/J 021225 STOCK Tg(Thy1-Brainbow3.1)3Jrs/J 021227 STOCK Tg(Thy1-Brainbow3.2)7Jrs/J 013162 STOCK Tg(Thy1-Clomeleon)12Gjau/J 013163 STOCK Tg(Thy1-Clomeleon)13Gjau/J 007788 STOCK Tg(Thy1-EGFP)MJrs/J 012708 STOCK Tg(Thy1-cre/ERT2,-EYFP)HGfng/PyngJView Strains carrying other alleles of Thy1 (93 strains)
View Research ApplicationsResearch ApplicationsThis mouse can be used to support research in many areas including:
Immunology, Inflammation and Autoimmunity Research
Behavioral and Learning Defects
Channel and Transporter Defects
Neurotransmitter Receptor and Synaptic Vesicle Defects
Immunology, Inflammation and Autoimmunity Research
|Allele Name||transgene insertion 300, Katrin Andreasson|
|Allele Type||Transgenic (Inserted expressed sequence)|
|Common Name(s)||Thy-1-COX-2 tg line 300; hCOX-2 tg;|
|Mutation Made By||Katrin Andreasson, Stanford University|
|Strain of Origin||C57BL/6J|
|Expressed Gene||PTGS2, prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase), human|
|Promoter||Thy1, thymus cell antigen 1, theta, mouse, laboratory|
|Molecular Note||The transgene construct contains the entire 1.8 kb human COX-2 (PTGS2; prostaglandin-endoperoxide synthase 2 or PGE2) open reading frame sequence inserted into the 8.2 kb Thy-1 expression cassette. This construct was injected into the male pronuclei of C57BL/6J cells. No founder lines were provided in the original reference but lines 300, 303, and 316 were characterized in subsequent publications. Mice from founder line 300 were found to have an approximately 10-12-fold increase in PGE2 expression. [MGI Ref ID J:72034]|
Andreasson KI; Savonenko A; Vidensky S; Goellner JJ; Zhang Y; Shaffer A; Kaufmann WE; Worley PF; Isakson P; Markowska AL. 2001. Age-dependent cognitive deficits and neuronal apoptosis in cyclooxygenase-2 transgenic mice. J Neurosci 21(20):8198-209. [PubMed: 11588192] [MGI Ref ID J:72034]
Dore S; Otsuka T; Mito T; Sugo N; Hand T; Wu L; Hurn PD; Traystman RJ; Andreasson K. 2003. Neuronal overexpression of cyclooxygenase-2 increases cerebral infarction. Ann Neurol 54(2):155-62. [PubMed: 12891667] [MGI Ref ID J:156166]
Melnikova T; Savonenko A; Wang Q; Liang X; Hand T; Wu L; Kaufmann WE; Vehmas A; Andreasson KI. 2006. Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern. Neuroscience 141(3):1149-62. [PubMed: 16753269] [MGI Ref ID J:111748]
Vidensky S; Zhang Y; hand T; Goellner J; Shaffer A; Isakson P; Andreasson K. 2003. Neuronal overexpression of COX-2 results in dominant production of PGE2 and altered fever response. Neuromolecular Med 3(1):15-28. [PubMed: 12665673] [MGI Ref ID J:156168]
Yang H; Zhang J; Andreasson K; Chen C. 2008. COX-2 oxidative metabolism of endocannabinoids augments hippocampal synaptic plasticity. Mol Cell Neurosci 37(4):682-95. [PubMed: 18295507] [MGI Ref ID J:135668]
|Pricing for USA, Canada and Mexico shipping destinations|
Cryopreserved Mice - Ready for Recovery
Price (US dollars $) Cryorecovery* $2140.00
At least two mice that carry the mutation (if it is a mutant strain) will be provided. Their genotypes may not reflect those discussed in the strain description. Please inquire for possible genotypes and see additional details below.
Cryorecovery - Standard.
Progeny testing is not required.
The average number of mice provided from recovery of our cryopreserved strains is 10. The total number of animals provided, their gender and genotype will vary. We will fulfill your order by providing at least two pair of mice, at least one animal of each pair carrying the mutation of interest. Please inquire if larger numbers of animals with specific genotype and genders are needed. Animals typically ship between 10 and 14 weeks from the date of your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will ship within 25 weeks. IMPORTANT NOTE: The genotypes of animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire about possible genotypes which will be recovered for this specific strain. The Jackson Laboratory cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.
Cryorecovery to establish a Dedicated Supply for greater quantities of mice. Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 (from U.S.A., Canada or Puerto Rico only) or 1-207-288-5845 (from any location).
|Pricing for International shipping destinations|
Cryopreserved Mice - Ready for Recovery
Price (US dollars $) Cryorecovery* $2782.00
Cryorecovery - Standard.
Progeny testing is not required.
|Considerations for Choosing Controls|
|Control Pricing Information for Genetically Engineered Mutant Strains.|
For Licensing and Use Restrictions view the link(s) below:
- Use of MICE by companies or for-profit entities requires a license prior to shipping.
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.
In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.
MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.
Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.